Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > IR update?

<< Previous

Bullboard Posts

Next >>

Comment by mikerodgeron Jun 07, 2011 8:10pm

373 Views

Post# 18684034

RE: IR update?

Adit123
There was one email from an investor that got lost in my email. If that was you, my apologies.
There is news expected in the next few weeks, but at this point Cue is continuing to move ahead despite the tragedy in Japan and its affect on the uranium market. We've started to see a recovery in the uranium price which I think will continue.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?